ProMIS Neurosciences Inc (PMN) saw an uptrend of 3.92% in the recent trading with $0.48 being its most recent. The current price level -70.00% lower than the highest price of $1.59 marked by the stock while trading over the past 52-weeks, whereas it is 25.53% higher than the lowest price of $0.38 the company dropped to over past 52-weeks. The latest news story on PMN appeared in (PR Newswire) under the title “Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics”.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
ProMIS Neurosciences Inc Earnings – What Happened With PMN
Coming around sales and income figures on PMN Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. ProMIS Neurosciences Inc (PMN) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 547.86% for net revenue.
PMN – ProMIS Neurosciences Inc Stock Earnings Estimates
The perspective of ProMIS Neurosciences Inc (NASDAQ:PMN)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.1 for stock’s EPS in the current quarter. ProMIS Neurosciences Inc (PMN) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 547.86% for net revenue. Company’s EPS for the last quarter was 0.43.
ProMIS Neurosciences Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 32.69 million. PMN does have institutional investors; and they hold 21.86% of the stock.
